| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by operating activities | 53,675 | 29,644 |
| Maturities of short-term investments | 47,580 | 26,850 |
| Purchases of short-term investments | 114,571 | 60,678 |
| Capital expenditures | 12 | - |
| Net cash (used in) provided by investing activities | -67,003 | -33,828 |
| Net proceeds from issuance of common stock from equity plans | 5,173 | 902 |
| Net cash provided by (used in) financing activities | 5,173 | 902 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -8,155 | -3,282 |
| Cash and cash equivalents at beginning of period | 56,746 | - |
| Cash and cash equivalents at end of period | 48,591 | - |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)